Sökning: onr:"swepub:oai:gup.ub.gu.se/292786" >
Swedish Isradipine ...
Swedish Isradipine Study in Hypertension: evaluation of quality of life, safety, and efficacy. SWISH Group.
-
- Jern, Sverker, 1954 (författare)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
Hansson, L (författare)
-
Scherstén, B (författare)
-
visa fler...
-
Kullman, S (författare)
-
Sörensen, S (författare)
-
- Dahlöf, Björn, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för internmedicin,Institute of Internal Medicine, Dept of Medicine
-
- Eggertsen, Robert, 1948 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för samhällsmedicin, Avdelningen för allmänmedicin,Institute of Community Medicine, Dept of Primary Health Care
-
Eivertsson, Ramon (författare)
-
visa färre...
-
(creator_code:org_t)
- 1991
- 1991
- Engelska.
-
Ingår i: Journal of cardiovascular pharmacology. - 0160-2446. ; 18 Suppl 3
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- This was a double-blind multicenter study to compare the efficacy, tolerability and effects on the quality of life with isradipine and atenolol in the treatment of essential hypertension. Of 588 patients entering the 6-week placebo run-in period, 549 were eligible for randomization to receive either isradipine or atenolol for 8 weeks. If, at the end of this period, diastolic blood pressure (DBP) remained greater than 90 mm Hg, then both agents were given in combination for a further 10 weeks. Tolerability and quality of life were assessed repeatedly during the placebo and active-treatment phases. A subgroup of 30 patients were followed by 24-h ambulatory blood pressure monitoring, and their results are now being analyzed. In another subgroup of 26 patients, maximum exercise capacity, as determined by ergometer bicycle-testing, was measured once during placebo and twice during active treatment. At the end of the 24-week study period, both isradipine and atenolol as monotherapy had produced significant decreases in blood pressure. There were no significant differences overall between the compounds in quality-of-life and side-effect profiles, although there was a relative absence of ankle edema and headache with isradipine. Furthermore, patients receiving isradipine had no change in performance on exercise testing whereas patients on atenolol had a significant decrease (p less than 0.01).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- Antihypertensive Agents
- therapeutic use
- Atenolol
- therapeutic use
- Blood Pressure
- drug effects
- Calcium Channel Blockers
- therapeutic use
- Dihydropyridines
- therapeutic use
- Double-Blind Method
- Humans
- Hypertension
- drug therapy
- Isradipine
- Middle Aged
- Prospective Studies
- Quality of Life
- Safety
- Sweden
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Jern, Sverker, 1 ...
-
Hansson, L
-
Scherstén, B
-
Kullman, S
-
Sörensen, S
-
Dahlöf, Björn, 1 ...
-
visa fler...
-
Eggertsen, Rober ...
-
Eivertsson, Ramo ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
Journal of cardi ...
- Av lärosätet
-
Göteborgs universitet